Education
About Us
Working with TipRanks
Follow Us
Immatics (IMTX)
NASDAQ:IMTX
IMTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.06 - $13.77
Previous CloseN/A
Volume408.80K
Average Volume (3M)778.30K
Market Cap
$552.62M
Enterprise Value$256.88M
Total Cash (Recent Filing)-€52.47M
Total Debt (Recent Filing)€808.50K
Price to Earnings (P/E)57.4
Beta1.07
Next Earnings
May 20, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding119,355,900
10 Day Avg. Volume942,174
30 Day Avg. Volume778,299
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.75
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$13.00Price Target Upside180.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Immatics News
PremiumCompany Announcements
Immatics Reports Strong 2024 Financial Results and Progress
PremiumCompany Announcements
Immatics Advances PRAME Cell Therapy and Expands Oncology Pipeline
PremiumCompany Announcements
Immatics Faces Termination of Key Collaboration with Bristol Myers SquibbPremiumCompany Announcements
Immatics N.V. Reports Strong Q3 2024 Progress and Financials---
Bulls Say, Bears Say
Bulls Say
Clinical DataImpressive data was reported for IMA203, with a 62% overall response rate and a 92% disease control rate in a heavily pre-treated metastatic melanoma patient group.
Financial PositionIMTX has a strong cash position with a financial runway into the second half of 2027.
Research And DevelopmentThe analyst maintains an overall positive view on Immatics N.V., with significant appreciation for the data generated for the company's lead assets and continued research and development execution.
Bears Say
Non-Melanoma EfficacyNo ongoing responses in non-melanoma tumors.
Partnership TerminationThe termination by Bristol Myers Squibb of a collaboration with Immatics N.V. is seen as an incremental negative for the stock.
Stock PerformanceIMTX shares dropped 16%, suspected to be related to the surprising decision to announce an equity financing.
---
Ownership Overview
―
Insiders
12.36% Mutual Funds
57.04% Other Institutional Investors
30.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMTX FAQ
What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was $4.06 and its highest was $13.77 in the past 12 months.
What is Immatics’s market cap?
Immatics’s market cap is $552.62M.
When is Immatics’s upcoming earnings report date?
Immatics’s upcoming earnings report date is May 20, 2025 which is in 50 days.
How were Immatics’s earnings last quarter?
Immatics released its earnings results on Mar 27, 2025. The company reported $0.495 earnings per share for the quarter, beating the consensus estimate of -$0.318 by $0.813.
Is Immatics overvalued?
According to Wall Street analysts Immatics’s price is currently Undervalued.
Does Immatics pay dividends?
Immatics does not currently pay dividends.
What is Immatics’s EPS estimate?
Immatics’s EPS estimate is -0.28.
How many shares outstanding does Immatics have?
Immatics has 119,355,900 shares outstanding.
What happened to Immatics’s price movement after its last earnings report?
Immatics reported an EPS of $0.495 in its last earnings report, beating expectations of -$0.318. Following the earnings report the stock price went up 3.974%.
Which hedge fund is a major shareholder of Immatics?
Currently, no hedge funds are holding shares in IMTX
---
Immatics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (180.78% Upside)
$13.00 (180.78% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.94%
12-Months-Change
Fundamentals
Return on Equity
3.73%
Trailing 12-Months
Asset Growth
27.96%
Trailing 12-Months
Company Description
Immatics
Immatics N.V. (IMTX) is a biotechnology company specializing in the development of novel T-cell receptor (TCR)-based immunotherapies for the treatment of cancer. The company operates primarily in the biomedical research and pharmaceuticals sectors, focusing on the discovery and development of therapies that harness the immune system to target and destroy cancer cells. Immatics is particularly engaged in the development of ACTengine®, a personalized cellular therapy, and XPRESIDENT®, a platform for the identification of novel cancer targets.
---
IMTX Stock 12 Month Forecast
Average Price Target
$13.00
▲(180.78% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering IMTX
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-20.47%
reiterated a buy rating 4 months ago
Copying Graig Suvannavejh's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -20.47% per trade.
---